Earnings · China A-shares
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. Class A (300937) earnings
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. Class A published its Q3 report on 2026-10-29: net profit -112.29% year on year, -84.31% excluding one-off items. Wave Radar's earnings-quality score is 59 of 100 (Questionable). The stock moved -3.23% in the 3 trading days after the report.
- Report
- Q3 report
- Published
- 2026-10-29
- Period end
- 2026-09-30
- Net profit YoY
- -112.29%
- Excl. one-offs YoY
- -84.31%
- Result
- Bad / loss
- Quality score
- 59
- Quality
- Questionable
Stock move after the report
Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.
| After | Return | vs index |
|---|---|---|
| 1 day | -3.37% | — |
| 3 days | -3.23% | — |
| 7 days | -4.37% | — |
| 14 days | -11.94% | — |
Report history
Over the last 8 reports, net profit grew year on year in 0 of them. The stock rose in the 3 trading days after 2 of 7 reports (average -1.51%).
| Report | Published | Net profit | Profit YoY | Excl. one-offs YoY | Revenue YoY | EPS | ROE | 3 days after | 30 days after | 30d vs index |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 Q3 report | 2026-10-30 | -¥23.42M | -112.29% | -84.31% | -1.23% | -0.24 | -2.91% | -3.23% | — | — |
| 2026 interim report | 2026-08-25 | -¥9.53M | -3.01% | -9.68% | +0.80% | -0.10 | -1.17% | +0.24% | -5.48% | +0.54% |
| 2026 Q1 report | 2026-04-29 | -¥2.72M | -165.02% | — | -2.08% | -0.03 | 0.04% | -1.29% | -22.27% | -23.21% |
| 2025 annual report | 2026-04-29 | -¥12.85M | -197.36% | — | +1.35% | -0.13 | -1.57% | -1.29% | -22.27% | -23.21% |
| 2025 Q3 report | 2025-10-24 | -¥8.36M | -159.98% | — | +0.21% | -0.09 | -0.99% | -0.40% | +26.99% | +27.21% |
| 2025 interim report | 2025-08-12 | -¥7.61M | -162.95% | — | -3.06% | -0.08 | -0.90% | -7.27% | -15.69% | -25.48% |
| 2025 Q1 report | 2025-04-25 | ¥4.18M | -54.65% | -41.49% | -8.06% | 0.04 | 0.49% | +0.00% | +15.24% | +11.99% |
| 2024 annual report | 2025-04-11 | ¥13.20M | -72.52% | -86.00% | -0.81% | 0.14 | 1.57% | +1.37% | +15.14% | +11.77% |
The last 8 reports. Net profit is attributable to shareholders and year-to-date (a Q3 report covers the first nine months). Moves count trading days from the first tradeable session after publication; "30d vs index" is the excess return over CSI 300.
How to read this
Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.